TapewireFind a company

person · Reporting owner

Hidalgo Medina Manuel

Disclosed activity across 2 companies

Tapewire entity
14988
SEC CIK
0001865525

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BRISTOL MYERS SQUIBB COBMY · Entity 1662DirectorFebruary 01, 2026February 03, 2026
Guardant Health, Inc.GH · Entity 3238DirectorSeptember 17, 2026September 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date February 01, 2026 · Filed February 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Deferred Share UnitsSEC Table II · derivative / convertible securityDirect22,763.938 Reported balance After 2026-02-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-01 · Grant · Acquired 3,996.367 · Balance 22,763.938

F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Filing footnotes · ownership attribution and instrument terms

F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Guardant Health, Inc.

Report date September 17, 2026 · Filed September 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect5,020 Reported balance After 2026-09-17 transaction · row 1
1 source row

Row 1 · 2026-09-17 · Exercise / conversion · Acquired 232 · Balance 5,020

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct5,105 Reported balance After 2026-09-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-17 · Exercise / conversion · Disposed 232 · Balance 5,105

F1: The restricted stock unit award granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on July 17, 2025 and the remaining 75% vests monthly for the three-year period thereafter.

F2: Not applicable for Restricted Stock Units.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock unit award granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on July 17, 2025 and the remaining 75% vests monthly for the three-year period thereafter.

F2: Not applicable for Restricted Stock Units.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 17, 2025 Filed Sep 18, 2025 20:33 UTC Guardant Health, Inc. GH · Entity 3238 Exercise / conversionCommon Stock 232 $0.00 $0.00
Disclosure

SEC source: 0001865525-25-000006 · wk-form4_1758227632.xml · nonDerivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,083

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 12, 2025 Filed Sep 15, 2025 21:09 UTC Guardant Health, Inc. GH · Entity 3238 SaleCommon Stock 2,165 $54.16 $117,250.77
Disclosure

SEC source: 0001865525-25-000004 · wk-form4_1757970581.xml · nonDerivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 851

F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $54.1501 to $54.1651. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
August 17, 2025 Filed Aug 18, 2025 21:44 UTC Guardant Health, Inc. GH · Entity 3238 Exercise / conversionRestricted Stock Units · Derivative 232 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001576280-25-000258 · wk-form4_1755553459.xml · derivative · entry 2

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,121

Underlying: Common Stock · 232 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock unit granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of July 17, 2024 and the remaining 75% vests monthly for the three-year period thereafter.

F2 · derivative.expiration_date: Not applicable for Restricted Stock Units.

Read SEC document
August 17, 2025 Filed Aug 18, 2025 21:44 UTC Guardant Health, Inc. GH · Entity 3238 Exercise / conversionCommon Stock 232 $0.00 $0.00
Disclosure

SEC source: 0001576280-25-000258 · wk-form4_1755553459.xml · nonDerivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,016

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 17, 2025 Filed Jul 18, 2025 21:22 UTC Guardant Health, Inc. GH · Entity 3238 Exercise / conversionRestricted Stock Units · Derivative 2,784 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001576280-25-000235 · wk-form4_1752873764.xml · derivative · entry 2

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,353

Underlying: Common Stock · 2,784 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock unit granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award will vest on the one-year anniversary of July 17, 2024, and the remaining 75% vests monthly for the three-year period thereafter.

F2 · derivative.expiration_date: Not applicable for Restricted Stock Units.

Read SEC document
July 17, 2025 Filed Jul 18, 2025 21:22 UTC Guardant Health, Inc. GH · Entity 3238 Exercise / conversionCommon Stock 2,784 $0.00 $0.00
Disclosure

SEC source: 0001576280-25-000235 · wk-form4_1752873764.xml · nonDerivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 18, 2025 Filed Jun 20, 2025 21:31 UTC Guardant Health, Inc. GH · Entity 3238 GrantRestricted Stock Units · Derivative 4,203 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001576280-25-000197 · wk-form4_1750455066.xml · derivative · entry 2

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,203

Underlying: Common Stock · 4,203 shares

Expires not disclosed

F2 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.

F3 · derivative.expiration_date: Not applicable for Restricted Stock Units.

Read SEC document
June 18, 2025 Filed Jun 20, 2025 21:31 UTC Guardant Health, Inc. GH · Entity 3238 GrantStock Option (Right to Buy) · Derivative 6,833 $0.00 Strike: $50.57 $0.00
Disclosure

SEC source: 0001576280-25-000197 · wk-form4_1750455066.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,833

Underlying: Common Stock · 6,833 shares

Expires 2035-06-18

F1 · derivative.exercise_date: The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.

Read SEC document
February 01, 2025 Filed Feb 5, 2025 00:16 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 3,562.341 $58.95 $210,000.00
Disclosure

SEC source: 0000014272-25-000022 · wk-form4_1738714558.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,835.638

Underlying: Common Stock, $0.10 par value · 3,562.341 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 22:26 UTC Guardant Health, Inc. GH · Entity 3238 GrantRestricted Stock Units · Derivative 11,137 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001576280-24-000182 · wk-form4_1721427991.xml · derivative · entry 2

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,137

Underlying: Common Stock · 11,137 shares

Expires not disclosed

F2 · derivative.exercise_date: The restricted stock unit granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award will vest on the one-year anniversary of July 17, 2024, and the remaining 75% vests monthly for the three-year period thereafter.

F3 · derivative.expiration_date: Not applicable for Restricted Stock Units.

Read SEC document
July 17, 2024 Filed Jul 19, 2024 22:26 UTC Guardant Health, Inc. GH · Entity 3238 GrantStock Option (Right to Buy) · Derivative 17,029 $0.00 Strike: $32.55 $0.00
Disclosure

SEC source: 0001576280-24-000182 · wk-form4_1721427991.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,029

Underlying: Common Stock · 17,029 shares

Expires 2034-07-17

F1 · derivative.exercise_date: The stock option granted on July 17, 2024 vests over a four-year period. 25% of the shares subject to such award will vest on the one-year anniversary of July 17, 2024, and the remaining 75% vests monthly for the three-year period thereafter.

Read SEC document
February 01, 2024 Filed Feb 6, 2024 00:21 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 4,314.773 $48.67 $210,000.00
Disclosure

SEC source: 0000014272-24-000030 · wk-form4_1707178847.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,616.16

Underlying: Common Stock, $0.10 par value · 4,314.773 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
December 31, 2023 Filed Jan 3, 2024 22:38 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 164.442 $51.31 $8,437.52
Disclosure

SEC source: 0000014272-24-000008 · wk-form4_1704321470.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,188.12

Underlying: Common Stock, $0.10 par value · 164.442 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
February 01, 2023 Filed Feb 4, 2023 00:17 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 2,807.806 $71.23 $200,000.02
Disclosure

SEC source: 0000014272-23-000030 · wf-form4_167546983917971.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,769.483

Underlying: Common Stock, $0.10 par value · 2,807.806 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
December 31, 2022 Filed Jan 4, 2023 22:24 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 117.269 $71.95 $8,437.50
Disclosure

SEC source: 0000014272-23-000014 · wf-form4_167287104945943.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,914.348

Underlying: Common Stock, $0.10 par value · 117.269 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
September 30, 2022 Filed Oct 5, 2022 01:12 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 118.688 $71.09 $8,437.53
Disclosure

SEC source: 0000014272-22-000187 · wf-form4_166493204951387.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,757.009

Underlying: Common Stock, $0.10 par value · 118.688 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
June 30, 2022 Filed Jul 5, 2022 20:30 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 97.403 $77.00 $7,500.03
Disclosure

SEC source: 0000014272-22-000160 · wf-form4_165705300313566.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,589.451

Underlying: Common Stock, $0.10 par value · 97.403 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 22:15 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 102.698 $73.03 $7,500.03
Disclosure

SEC source: 0000014272-22-000108 · wf-form4_164911049423449.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,452.829

Underlying: Common Stock, $0.10 par value · 102.698 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 23:02 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 3,067.955 $65.19 $199,999.99
Disclosure

SEC source: 0000014272-22-000035 · wf-form4_164392933198331.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,350.131

Underlying: Common Stock, $0.10 par value · 3,067.955 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 23:19 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 115.277 $62.35 $7,187.52
Disclosure

SEC source: 0000014272-22-000011 · wf-form4_164133835430648.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,232.837

Underlying: Common Stock, $0.10 par value · 115.277 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
September 30, 2021 Filed Oct 1, 2021 20:31 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 121.472 $0.00 $0.00
Disclosure

SEC source: 0000014272-21-000218 · wf-form4_163312024987329.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,116.248

Underlying: Common Stock, $0.10 par value · 121.472 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
June 30, 2021 Filed Jul 1, 2021 21:13 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 35.461 $0.00 $0.00
Disclosure

SEC source: 0000014272-21-000173 · wf-form4_162517397238754.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,994.52

Underlying: Common Stock, $0.10 par value · 35.461 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:43 UTC BRISTOL MYERS SQUIBB CO BMY · Entity 1662 GrantDeferred Share Units · Derivative 1,959.059 $65.10 $127,534.74
Disclosure

SEC source: 0000014272-21-000140 · wf-form4_162275291539348.xml · derivative · entry 1

Hidalgo Medina Manuel · CIK 0001865525 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,959.059

Underlying: Common Stock, $0.10 par value · 1,959.059 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · shares: Represents pro rata portion of the 2021 annual Deferred Share Unit awards granted to the Company's directors.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.